Skip to main content
Premium Trial:

Request an Annual Quote

Sistemic, Roslin Cells Partner to Establish Stem Cell Manufacturing Standards

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sistemic and Roslin Cells today announced a memorandum of understanding to promote technologies to standardize the manufacture of stem cells for use in cell therapy and drug development screening.

Financial and other terms of the MOU were not disclosed.

In a statement, Jim Reid, Sistemic's CEO, said that in its work with clients, the company has found "that there is a general consensus within the stem cell community that the currently available tools and technologies are not truly fit for purpose." He added that Sistemic in collaboration with Roslin will "set the standard for stem cell characterization and quality."

Based in Glasgow, UK, Sistemic develops miRNA-based services and kit-based products for the pharmaceutical, biotechnology, and cell therapy markets. Roslin Cells is a non-profit organization established by the Roslin Institute, with the goal of providing ethically sourced, pluripotent human cells.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.